Hepatocellular carcinoma
Ontology highlight
ABSTRACT:
SUBMITTER:
PROVIDER: S-DIXA-D-1027 | biostudies-other |
REPOSITORIES: biostudies-other
Similar Datasets
Project description:Spatial transcriptome on human hepatocellular carcinoma
| PRJEB62485 | ENA
Project description:Fibrolamellar hepatocellular carcinoma (FL-HCC) has historically been classified as a rare subtype of HCC. However, unlike "classic" HCC, it occurs in children and young adults without underlying liver disease. The recent discovery of a deletion mutation in all FL-HCCs represented a major advancement in understanding the pathogenesis of this disease. This deletion results in the fusion of the genes encoding a heat shock protein (DNAJB1) and the catalytic subunit of protein kinase A (PKA, PRKACA), and overexpression of PRKACA and enhanced cAMP-dependent PKA activity. This review summarizes recent advancements in FL-HCC pathogenesis and characteristics of the HSP40-PKA C protein.
| S-EPMC4877189 | biostudies-literature
Project description:Transcription profiling of pair-matched tumor and adjacent liver tissues from 56 HCC patients were performed using cDNA microarray. Keywords: Disease state analysis Common reference. One replicate per array.
2009-02-12 | E-GEOD-14811 | biostudies-arrayexpress
Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
2014-12-10 | E-GEOD-57958 | biostudies-arrayexpress
Project description:Transcription profiling of pair-matched tumor and adjacent liver tissues from 56 HCC patients were performed using cDNA microarray. Keywords: Disease state analysis
2009-02-13 | GSE14811 | GEO
Project description:This SuperSeries is composed of the SubSeries listed below.
2014-12-10 | GSE57958 | GEO
Project description:Newer immunotherapy agents may break the barrier that tumors create to evade the attack from the immune system. Dendritic cell vaccination has shown encouraging clinical activity and a favorable safety profile in advanced tumor stages. However, optimal cell maturation status, choice of tumor antigens and route of administration have not been established. Single or multiple peptides derived from tumor-associated antigens may also be used for cancer vaccination. Intratumoral delivery of oncolytic viruses expressing immunostimulating cytokines like GM-CSF have produced stimulating clinical results that need further verification. But it is probably T-cell checkpoint modulation with monoclonal antibodies that has attracted the highest expectations. Promising activity has been reported for tremelimumab, a CTLA-4 inhibitor, and a clinical trial testing the PD-1 antibody nivolumab is underway. Future progress will probably come from a better understanding of the mechanisms of cancer-related immunosuppression, improvement in agents and strategies and combination of the available therapeutic tools.
| S-EPMC6095173 | biostudies-other
Project description:Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and relatively preserved liver function. In a meta-analysis of randomized controlled trials comparing conventional TACE regimens-including the administration of an anticancer-in-oil emulsion followed by embolic agents-versus best supportive care, TACE was shown to improve median survival from 16 to 20 months. Various strategies to improve outcomes for this patient group have become the subject of much ongoing clinical research. The introduction of an embolic drug-eluting bead (DEB) has been shown to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability not available with conventional regimens while concomitantly significantly diminishing systemic drug exposure. In randomized trials, DEB-TACE significantly reduced liver toxicity and drug-related adverse events compared with conventional TACE. In this article, technique, indications and contraindications, and clinical outcomes of conventional and DEB-TACE in the management of HCC are reviewed. In addition, scientific background and early clinical experience with the use of combination regimens including TACE and systemically active molecular-targeted agents with antiangiogenic properties are discussed. The combination of DEB-TACE and antiangiogenic therapy represents a potentially powerful approach that is currently undergoing clinical investigation in a phase 3 setting.
| S-EPMC3700789 | biostudies-other
Project description: Not available
| S-DIXA-D-1050 | biostudies-other
Project description:Shotgun LC-MS/MS was performed on immunoaffinity purified TBC1D15-interacting proteins. We searched for in vivo partners of TBC1D15-mediated regulation by large-scale immunoaffinity purification of interacting proteins of endogenous TBC1D15 in TICs and Identification of interaction partners was accomplished by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This approach identified several high-confidence interacting proteins, including NuMA1, NOTCH1/2/3/4 and RANGAP1.
2020-04-22 | MSV000085321 | MassIVE